INSM vs. NBIX: Insmed vs. Neurocrine Biosciences Stock Comparison
How do Insmed (INSM) and Neurocrine Biosciences (NBIX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Insmed (INSM) and Neurocrine Biosciences (NBIX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | INSM | NBIX |
|---|---|---|
| Name | Insmed Incorporated | Neurocrine Biosciences, Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 25.10 billion USD | 16.66 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 1, 2000 | May 23, 1996 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | INSM | NBIX |
|---|---|---|
| Total Return (1Y) | -39.17% | 9.40% |
| Total Return (3Y, Annualized) | 70.17% | 14.12% |
| Total Return (5Y, Annualized) | 28.96% | 12.61% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | INSM | NBIX |
|---|---|---|
| Volatility (1Y, Annualized) | 63.09% | 35.05% |
| Beta (5Y) | 0.80 | 0.29 |
| Max Drawdown (5Y) | -56.54% | -42.89% |
| Avg. Volume (3M) | 2.76M | 1.31M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | INSM | NBIX |
|---|---|---|
| Sharpe Ratio (1Y) | -0.69 | 0.15 |
| Sortino Ratio (1Y) | -1.04 | 0.22 |
Profitability
ROE (TTM)
Insmed (INSM) reports a negative ROE of -72.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Neurocrine Biosciences (NBIX) reports 20.42%, ranking against industry peers normally.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-72.45%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- INSM
- -72.45%
- Min
- -167.77%
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.42%
- Max
- 109.18%
- NBIX
- 20.42%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Insmed (INSM) reports a negative net margin of -39.85%, usually indicating a net loss over the period. Meanwhile Neurocrine Biosciences (NBIX) reports 18.98%, ranking against industry peers normally.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-39.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- INSM
- -39.85%
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.98%
- NBIX
- 18.98%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Insmed (INSM) reports a negative operating margin of -15.60%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Neurocrine Biosciences (NBIX) reports 31.98%, ranking against industry peers normally.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-15.60%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- INSM
- -15.60%
- Q1
- -78.82%
- Min
- -207.40%
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.98%
- Max
- 83.12%
- NBIX
- 31.98%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | INSM | NBIX |
|---|---|---|
| ROE (TTM) | -72.45% | 20.42% |
| ROA (TTM) | -17.25% | 12.45% |
| Net Margin (TTM) | -39.85% | 18.98% |
| Operating Margin (TTM) | -15.60% | 31.98% |
| Gross Margin (TTM) | 84.40% | 64.67% |
Growth
Revenue Growth
Insmed (INSM) at 66.73% sits in the top revenue growth quartile, while Neurocrine Biosciences (NBIX) at 21.45% is closer to the peer norm — faster top-line expansion for INSM.
EPS Growth
Only one side can be read here: Neurocrine Biosciences (NBIX) reports EPS growth of 41.95%, ranked against its industry; Insmed (INSM) has no EPS growth figure this period.
Growth Metrics
| Metric | INSM | NBIX |
|---|---|---|
| Revenue Growth (YoY) | 66.73% | 21.45% |
| Revenue Growth (3Y CAGR) | 35.20% | 24.32% |
| EPS Growth (YoY) | -- | 41.95% |
| EPS Growth (3Y CAGR) | -- | 44.12% |
Financial Strength
Current Ratio (MRQ)
Insmed (INSM) at 2.86 keeps current ratio within its industry’s typical mid-range, while Neurocrine Biosciences (NBIX) at 2.04 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NBIX.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.86
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- INSM
- 2.86
- Q1
- 2.47
- Min
- 0.10
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.04
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- NBIX
- 2.04
- Min
- 0.10
Debt / Equity (MRQ)
Neurocrine Biosciences (NBIX) at 0.12 carries an industry-typical debt-to-equity mix, while Insmed (INSM) at 1.01 uses more debt funding than most peers.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.01
- Max
- 1.42
- INSM
- 1.01
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.12
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- NBIX
- 0.12
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | INSM | NBIX |
|---|---|---|
| Current Ratio (MRQ) | 2.86 | 2.04 |
| Debt / Equity (MRQ) | 1.01 | 0.12 |
| Net Debt / EBITDA | -- | -0.27 |
Dividends
Dividend Yield (TTM)
Neither Insmed (INSM) nor Neurocrine Biosciences (NBIX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INSM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NBIX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Insmed (INSM) nor Neurocrine Biosciences (NBIX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INSM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NBIX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | INSM | NBIX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Neurocrine Biosciences (NBIX) trades at 24.43 times trailing earnings, ranked against its peers, while Insmed (INSM) has no P/E ratio this period.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- INSM
- --
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
24.43
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- NBIX
- 24.43
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Insmed (INSM) at 16.52 and Neurocrine Biosciences (NBIX) at 4.50 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.52
- Max
- 58.18
- Q3
- 25.77
- INSM
- 16.52
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.50
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- NBIX
- 4.50
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Neurocrine Biosciences (NBIX) at 4.30 sits near its industry’s typical P/B ratio, while Insmed (INSM) at 34.55 prices above its benchmark range — INSM looks rich relative to book.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.55
- INSM
- 34.55
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.30
- Max
- 13.53
- Q3
- 6.54
- NBIX
- 4.30
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | INSM | NBIX |
|---|---|---|
| P/E Ratio (TTM) | -- | 24.43 |
| P/S Ratio (TTM) | 16.52 | 4.50 |
| P/B Ratio (MRQ) | 34.55 | 4.30 |
| Free Cash Flow Yield (TTM) | -1.82% | 6.11% |